Tonix Pharmaceuticals (OTCBB: TNXP) develops new treatments for challenging disorders of the central nervous system (CNS).

The Company’s lead programs are potential new treatments for fibromyalgia and post-traumatic stress disorder, which are chronic CNS syndromes. In each of these programs, TONIX seeks to use new doses and formulations of cyclobenzaprine in new treatment regimens. Cyclobenzaprine is the active ingredient of two prescription muscle relaxants that have been approved by the U.S. Food and Drug Administration (FDA) and are marketed by other companies.

For additional information, please visit www.tonixpharma.com.